For immediate release |
12 April 2022 |
ALLIANCE PHARMA
("Alliance" or the "Group")
Posting of Annual Report and Notice of AGM
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Annual Report and Accounts for the year ended 31 December 2021, and the notice of the 2022 AGM meeting to be held on 18 May, have now been posted to those shareholders who have opted out of receiving electronic communications from the Group.
Printed copies of the documents are also available by contacting Buchanan by email at alliancepharma@buchanan.uk.com or by telephoning Buchanan on 020 7466 5000.
For further information:
Alliance Pharma plc |
+ 44 (0)1249 466966 |
Cora McCallum, Head of Investor Relations & Corporate Communications |
+ 44 (0)1249 705168 |
|
|
|
|
Buchanan |
+ 44 (0)20 7466 5000 |
Mark Court / Sophie Wills / Hannah Ratcliff |
|
|
|
|
|
Numis Securities Limited |
+ 44 (0)20 7260 1000 |
Nominated Adviser: Freddie Barnfield / Duncan Monteith |
|
Corporate Broking: James Black |
|
|
|
Investec Bank plc |
+ 44 (0)20 7597 5970 |
Corporate Finance: Daniel Adams |
|
Corporate Broking: Patrick Robb |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.
For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com